Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-04-30 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing FDA approval of a drug (Afinitor) for a new indication. It provides detailed clinical trial results, drug information, safety information, and forward-looking statements. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing that provides material information to investors and the SEC but does not fit into categories like earnings release, annual report, or capital update. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous reports of material events by foreign private issuers. The document length is substantial (15,000 characters), and it contains substantive information, but it is not a financial report per se. Therefore, the appropriate classification is Regulatory Filings (RNS).
2012-04-30 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains a media release announcing the approval of a drug (Signifor) in the EU, including clinical trial data and safety information. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about the company and its products to the SEC and investors. The length (15,000 characters) and content indicate it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2012-04-26 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC referencing the Form 20-F for the fiscal year ended December 31, 2011, which was filed on January 25, 2012. The letter discusses an extension of time to respond to an SEC inquiry. The document is short (1096 characters) and is a correspondence related to a regulatory filing rather than the filing itself. It does not contain financial data or the report itself but is a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS).
2012-04-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It references exhibits including a Financial Report for Q1 2012 and an Interim Financial Report. The document itself is short (1513 characters) and primarily serves as a cover or transmittal document for these reports rather than containing substantive financial data. According to the MENU VS MEAL RULE, such a document that announces or transmits reports but does not contain the reports themselves should be classified as a Regulatory Filing (RNS).
2012-04-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing an update to the US label for the drug Gilenya following discussions with the FDA. It provides detailed information about the label changes, patient guidance, and safety recommendations. The document does not contain financial statements or comprehensive financial data, nor is it an annual or quarterly report. It is not a certification or a voting result announcement. The document is a regulatory announcement about a product label update and related regulatory discussions. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (9448 characters) and detailed content confirm it is not a brief announcement of a report but a substantive regulatory communication.
2012-04-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing the recommendation by the CHMP for EU approval of the drug Jakavi for treating myelofibrosis. It contains detailed information about the drug, clinical trial results, and regulatory status but does not include financial statements or detailed financial performance data. The document is a regulatory announcement about a drug approval process and clinical data rather than a financial report or earnings release. It is not an annual or interim report, nor a call transcript or management report. Given the nature of the document as a regulatory filing reporting material company news and regulatory developments, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), so it is not a mere announcement of a report publication but a full regulatory communication. Therefore, the classification is RNS with high confidence.
2012-04-20 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.